Bacterial Infections in Acute-on-Chronic Liver Failure

J Fernández, 2002, Bacterial infections in cirrhosis: epidemiological changes with invasive procedures and norfloxacin prophylaxis, Hepatology, 35, 140, 10.1053/jhep.2002.30082

J S Bajaj, 2012, Second infections independently increase mortality in hospitalized patients with cirrhosis: the North American consortium for the study of end-stage liver disease (NACSELD) experience, Hepatology, 56, 2328, 10.1002/hep.25947

J S Bajaj, 2012, Bacterial infections in end-stage liver disease: current challenges and future directions, Gut, 61, 1219, 10.1136/gutjnl-2012-302339

J Fernández, 2012, Prevalence and risk factors of infections by multiresistant bacteria in cirrhosis: a prospective study, Hepatology, 55, 1551, 10.1002/hep.25532

V Arvaniti, 2010, Infections in patients with cirrhosis increase mortality four-fold and should be used in determining prognosis, Gastroenterology, 139, 1246, 10.1053/j.gastro.2010.06.019

P Nahon, 2017, Bacterial infection in compensated viral cirrhosis impairs 5-year survival (ANRS CO12 CirVir prospective cohort), Gut, 66, 330, 10.1136/gutjnl-2015-310275

J S Bajaj, 2014, Survival in infection-related acute-on-chronic liver failure is defined by extrahepatic organ failures, Hepatology, 60, 250, 10.1002/hep.27077

R Hernaez, 2017, Acute-on-chronic liver failure: an update, Gut, 66, 541, 10.1136/gutjnl-2016-312670

R Moreau, 2013, Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis, Gastroenterology, 144, 1426, 10.1053/j.gastro.2013.02.042

S K Sarin, 2014, Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific Association for the Study of the Liver (APASL) 2014, Hepatol Int, 8, 453, 10.1007/s12072-014-9580-2

T Wu, 2017, Development of diagnostic criteria and a prognostic score for hepatitis B virus-related acute-on-chronic liver failure, Gut, 10.1136/gutjnl-2017-314641

Y Shi, 2015, Acute-on-chronic liver failure precipitated by hepatic injury is distinct from that precipitated by extrahepatic insults, Hepatology, 62, 232, 10.1002/hep.27795

M M Mücke, 2018, Bacterial infection-triggered acute-on-chronic liver failure is associated with increased mortality, Liver Int, 38, 645, 10.1111/liv.13568

J Fernández, 2017, Bacterial and fungal infections in acute-on-chronic liver failure: prevalence, characteristics and impact on prognosis, Gut, 10.1136/gutjnl-2017-314240

H Li, 2016, Characteristics, diagnosis and prognosis of acute-on-chronic liver failure in cirrhosis associated to hepatitis B, Sci Rep, 6, 25487, 10.1038/srep25487

W R Caly, 1993, A prospective study of bacterial infections in patients with cirrhosis, J Hepatol, 18, 353, 10.1016/S0168-8278(05)80280-6

H Yoshida, 1993, Bacterial infection in cirrhosis, with and without hepatocellular carcinoma, Am J Gastroenterol, 88, 2067

M Deschênes, 1999, Risk factors for the development of bacterial infections in hospitalized patients with cirrhosis, Am J Gastroenterol, 94, 2193, 10.1111/j.1572-0241.1999.01293.x

A M Thulstrup, 2000, Population-based study of the risk and short-term prognosis for bacteremia in patients with liver cirrhosis, Clin Infect Dis, 31, 1357, 10.1086/317494

M Merli, 2016, An empirical broad spectrum antibiotic therapy in health-care-associated infections improves survival in patients with cirrhosis: a randomized trial, Hepatology, 63, 1632, 10.1002/hep.28332

J Fernández, 2016, The challenges of multi-drug-resistance in hepatology, J Hepatol, 65, 1043, 10.1016/j.jhep.2016.08.006

T Gustot, 2014, Impact of infection on the prognosis of critically ill cirrhotic patients: results from a large worldwide study, Liver Int, 34, 1496, 10.1111/liv.12520

C J Karvellas, 2010, Bacteremia, acute physiology and chronic health evaluation II and modified end stage liver disease are independent predictors of mortality in critically ill nontransplanted patients with acute on chronic liver failure, Crit Care Med, 38, 121, 10.1097/CCM.0b013e3181b42a1c

S K Sarin, 2009, Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific Association for the Study of the Liver (APASL), Hepatol Int, 3, 269, 10.1007/s12072-008-9106-x

H E Wasmuth, 2005, Patients with acute on chronic liver failure display “sepsis-like” immune paralysis, J Hepatol, 42, 195, 10.1016/j.jhep.2004.10.019

R Jalan, 2014, Bacterial infections in cirrhosis: a position statement based on the EASL Special Conference 2013, J Hepatol, 60, 1310, 10.1016/j.jhep.2014.01.024

P Tandon, 2015, Risk of bacterial infection in patients with cirrhosis and acute variceal hemorrhage, based on Child-Pugh class, and effects of antibiotics, Clin Gastroenterol Hepatol, 13, 1189, 10.1016/j.cgh.2014.11.019

A Albillos, 2014, Cirrhosis-associated immune dysfunction: distinctive features and clinical relevance, J Hepatol, 61, 1385, 10.1016/j.jhep.2014.08.010

J M Ramos, 2016, Comparison of the in vitro susceptibility of rifaximin versus norfloxacin against multidrug resistant bacteria in a hospital setting. A proof-of-concept study for use in advanced cirrhosis, Gut, 65, 182, 10.1136/gutjnl-2015-309421

G Dam, 2016, Proton pump inhibitors as a risk factor for hepatic encephalopathy and spontaneous bacterial peritonitis in patients with cirrhosis with ascites, Hepatology, 64, 1265, 10.1002/hep.28737

J Fernández, 2016, Antibiotic prophylaxis in cirrhosis: Good and bad, Hepatology, 63, 2019, 10.1002/hep.28330

T Gustot, 2017, Sepsis in alcohol-related liver disease, J Hepatol, 67, 1031, 10.1016/j.jhep.2017.06.013

A Louvet, 2009, Infection in patients with severe alcoholic hepatitis treated with steroids: early response to therapy is the key factor, Gastroenterology, 137, 541, 10.1053/j.gastro.2009.04.062

K Sargenti, 2015, Bacterial infections in alcoholic and nonalcoholic liver cirrhosis, Eur J Gastroenterol Hepatol, 27, 1080, 10.1097/MEG.0000000000000396

N Vergis, 2017, In patients with severe alcoholic hepatitis, prednisolone increases susceptibility to infection and infection-related mortality, and is associated with high circulating levels of bacterial DNA, Gastroenterology, 152, 1068, 10.1053/j.gastro.2016.12.019

T Thévenot, 2015, Effect of albumin in cirrhotic patients with infection other than spontaneous bacterial peritonitis. A randomized trial, J Hepatol, 62, 822, 10.1016/j.jhep.2014.11.017

F Wong, 2013, New consensus definition of acute kidney injury accurately predicts 30-day mortality in patients with cirrhosis and infection, Gastroenterology, 145, 1280, 10.1053/j.gastro.2013.08.051

A Plessier, 2003, Coagulation disorders in patients with cirrhosis and severe sepsis, Liver Int, 23, 440, 10.1111/j.1478-3231.2003.00870.x

M Merli, 2013, Increased risk of cognitive impairment in cirrhotic patients with bacterial infections, J Hepatol, 59, 243, 10.1016/j.jhep.2013.03.012

M Singer, 2016, The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3), JAMA, 315, 801, 10.1001/jama.2016.0287

T Gustot, 2009, Severe sepsis in cirrhosis, Hepatology, 50, 2022, 10.1002/hep.23264

J Clària, 2016, Systemic inflammation in decompensated cirrhosis: characterization and role in acute-on-chronic liver failure, Hepatology, 64, 1249, 10.1002/hep.28740

2016, Incidence of severe sepsis and septic shock in German intensive care units: the prospective, multicentrle INSEP study, Intensive Care Med, 42, 1980, 10.1007/s00134-016-4504-3

J D Twilla, 2016, Severity of systemic inflammatory response syndrome affects outcomes in decompensated cirrhotics with spontaneous bacterial peritonitis, Am J Gastroenterol, 111, 1043, 10.1038/ajg.2016.146

P Angeli, 2016, Sepsis-induced acute kidney injury in patients with cirrhosis, Hepatol Int, 10, 115, 10.1007/s12072-015-9641-1

A Galbois, 2015, Exploration of skin perfusion in cirrhotic patients with septic shock, J Hepatol, 62, 549, 10.1016/j.jhep.2014.10.012

R Jalan, 2012, Role of predisposition, injury, response and organ failure in the prognosis of patients with acute-on-chronic liver failure: a prospective cohort study, Crit Care, 16, R227, 10.1186/cc11882

J Michelena, 2015, Systemic inflammatory response and serum lipopolysaccharide levels predict multiple organ failure and death in alcoholic hepatitis, Hepatology, 62, 762, 10.1002/hep.27779

A Katoonizadeh, 2010, Early features of acute-on-chronic alcoholic liver failure: a prospective cohort study, Gut, 59, 1561, 10.1136/gut.2009.189639

H Tilg, 2016, Gut microbiome and liver diseases, Gut, 65, 2035, 10.1136/gutjnl-2016-312729

J S Bajaj, 2014, Altered profile of human gut microbiome is associated with cirrhosis and its complications, J Hepatol, 60, 940, 10.1016/j.jhep.2013.12.019

C P Hackstein, 2017, Gut microbial translocation corrupts myeloid cell function to control bacterial infection during liver cirrhosis, Gut, 66, 507, 10.1136/gutjnl-2015-311224

N Selvapatt, 2014, Understanding infection susceptibility in patients with acute-on-chronic liver failure, Intensive Care Med, 40, 1363, 10.1007/s00134-014-3349-x

C Bernsmeier, 2015, Immunotherapy in the treatment and prevention of infection in acute-on-chronic liver failure, Immunotherapy, 7, 641, 10.2217/imt.15.27

C Bernsmeier, 2017, CD14+CD15-HLA-DR- myeloid-derived suppressor cells impair antimicrobial responses in patients with acute-on-chronic liver failure, Gut, 10.1136/gutjnl-2017-314184

B Appenrodt, 2010, Nucleotide-binding oligomerization domain containing 2 (NOD2) variants are genetic risk factors for death and spontaneous bacterial peritonitis in liver cirrhosis, Hepatology, 51, 1327, 10.1002/hep.23440

R Senkerikova, 2014, Genetic variation in TNFA predicts protection from severe bacterial infections in patients with end-stage liver disease awaiting liver transplantation, J Hepatol, 60, 773, 10.1016/j.jhep.2013.12.011

C Bernsmeier, 2015, Patients with acute-on-chronic liver failure have increased numbers of regulatory immune cells expressing the receptor tyrosine kinase MERTK, Gastroenterology, 148, 603, 10.1053/j.gastro.2014.11.045

A Choudhury, 2017, Systemic inflammatory response syndrome in acute-on-chronic liver failure: relevance of ‘golden window’: a prospective study, J Gastroenterol Hepatol, 32, 1989, 10.1111/jgh.13799

M Merli, 2010, Cirrhotic patients are at risk for health care-associated bacterial infections, Clin Gastroenterol Hepatol, 8, 979, 10.1016/j.cgh.2010.06.024

2010, EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis, J Hepatol, 53, 397, 10.1016/j.jhep.2010.05.004

L A Mandell, 2015, Community-acquired pneumonia, N Engl J Med, 372, 293

M Boaretti, 2016, Presence of multiple bacterial markers in clinical samples might be useful for presumptive diagnosis of infection in cirrhotic patients with culture-negative reports, Eur J Clin Microbiol Infect Dis, 35, 433, 10.1007/s10096-015-2556-x

M Papp, 2012, Acute phase proteins in the diagnosis and prediction of cirrhosis associated bacterial infections, Liver Int, 32, 603, 10.1111/j.1478-3231.2011.02689.x

K H Lin, 2014, Serum procalcitonin and C-reactive protein levels as markers of bacterial infection in patients with liver cirrhosis: a systematic review and meta-analysis, Diagn Microbiol Infect Dis, 80, 72, 10.1016/j.diagmicrobio.2014.03.029

M A Parsi, 2008, Ascitic fluid lactoferrin for diagnosis of spontaneous bacterial peritonitis, Gastroenterology, 135, 803, 10.1053/j.gastro.2008.05.045

H Enomoto, 2012, Development of a new in situ hybridization method for the detection of global bacterial DNA to provide early evidence of a bacterial infection in spontaneous bacterial peritonitis, J Hepatol, 56, 85, 10.1016/j.jhep.2011.06.025

M Papp, 2013, High prevalence of IgA class anti-neutrophil cytoplasmic antibodies (ANCA) is associated with increased risk of bacterial infection in patients with cirrhosis, J Hepatol, 59, 457, 10.1016/j.jhep.2013.04.018

T Tornai, 2016, Macrophage activation marker, soluble CD163, is an independent predictor of short-term mortality in patients with cirrhosis and bacterial infection, Liver Int, 36, 1628, 10.1111/liv.13133

Y Wu, 2016, Serum interleukin-6 in the diagnosis of bacterial infection in cirrhotic patients: A meta-analysis, Medicine (Baltimore), 95, e5127, 10.1097/MD.0000000000005127

J Xin, 2016, Serum macrophage inflammatory protein 3α levels predict the severity of HBV-related acute-on-chronic liver failure, Gut, 65, 355, 10.1136/gutjnl-2015-309916

D K Kang, 2014, Rapid detection of single bacteria in unprocessed blood using Integrated Comprehensive Droplet Digital Detection, Nat Commun, 5, 5427, 10.1038/ncomms6427

H Shen, 2016, Rapid and selective detection of pathogenic bacteria in bloodstream infections with aptamer-based recognition, ACS Appl Mater Interfaces, 8, 19371, 10.1021/acsami.6b06671

Z Cao, 2017, The role of bacterial infection (BI) in decompensated cirrhosis patients with or without acute-on-chronic liver failure (ACLF), J Hepatol, 66, S344, 10.1016/S0168-8278(17)31020-6

J Fernández, 2012, Management of bacterial infections in cirrhosis, J Hepatol, 56, S1, 10.1016/S0168-8278(12)60002-6

J Fernández, 2007, Primary prophylaxis of spontaneous bacterial peritonitis delays hepatorenal syndrome and improves survival in cirrhosis, Gastroenterology, 133, 818, 10.1053/j.gastro.2007.06.065

P Ginés, 1990, Norfloxacin prevents spontaneous bacterial peritonitis recurrence in cirrhosis: results of a double-blind, placebo-controlled trial, Hepatology, 12, 716, 10.1002/hep.1840120416

J Fernández, 2006, Norfloxacin vs ceftriaxone in the prophylaxis of infections in patients with advanced cirrhosis and hemorrhage, Gastroenterology, 131, 1049, 10.1053/j.gastro.2006.07.010

R Terg, 2008, Ciprofloxacin in primary prophylaxis of spontaneous bacterial peritonitis: a randomized, placebo-controlled study, J Hepatol, 48, 774, 10.1016/j.jhep.2008.01.024

S Lontos, 2008, Norfloxacin and trimethoprim-sulfamethoxazole therapy have similar efficacy in prevention of spontaneous bacterial peritonitis, J Gastroenterol Hepatol, 23, 252, 10.1111/j.1440-1746.2007.04926.x

S Lontos, 2014, A randomized controlled study of trimethoprim-sulfamethoxazole versus norfloxacin for the prevention of infection in cirrhotic patients, J Dig Dis, 15, 260, 10.1111/1751-2980.12132

K Yan, 2016, Novel prevention strategies for bacterial infections in cirrhosis, Expert Opin Pharmacother, 17, 689, 10.1517/14656566.2016.1145663

R Wiest, 2017, Targeting the gut-liver axis in liver disease, J Hepatol, 67, 1084, 10.1016/j.jhep.2017.05.007

S M Riordan, 2006, The intestinal flora and bacterial infection in cirrhosis, J Hepatol, 45, 744, 10.1016/j.jhep.2006.08.001

V Stadlbauer, 2008, Effect of probiotic treatment on deranged neutrophil function and cytokine responses in patients with compensated alcoholic cirrhosis, J Hepatol, 48, 945, 10.1016/j.jhep.2008.02.015

J S Bajaj, 2014, Randomised clinical trial: Lactobacillus GG modulates gut microbiome, metabolome and endotoxemia in patients with cirrhosis, Aliment Pharmacol Ther, 39, 1113, 10.1111/apt.12695

A Meiphani, 2016, Successful outcomes of fecal microbiota transplantation in patients with chronic liver disease, Hepatology, 64, 1016A

J S Bajaj, 2017, Fecal microbiota transplant from a rational stool donor improves hepatic encephalopathy: a randomized clinical trial, Hepatology, 66, 1727, 10.1002/hep.29306

M Merli, 2015, The chronic use of beta-blockers and proton pump inhibitors may affect the rate of bacterial infections in cirrhosis, Liver Int, 35, 362, 10.1111/liv.12593

M Úbeda, 2016, Obeticholic acid reduces bacterial translocation and inhibits intestinal inflammation in cirrhotic rats, J Hepatol, 64, 1049, 10.1016/j.jhep.2015.12.010

B S Madsen, 2013, Targeting the gut-liver axis in cirrhosis: antibiotics and non-selective β-blockers, Adv Ther, 30, 659, 10.1007/s12325-013-0044-1

R P Mookerjee, 2016, Treatment with non-selective beta blockers is associated with reduced severity of systemic inflammation and improved survival of patients with acute-on-chronic liver failure, J Hepatol, 64, 574, 10.1016/j.jhep.2015.10.018

R de Franchis, 2015, Expanding consensus in portal hypertension: report of the Baveno VI Consensus Workshop: stratifying risk and individualizing care for portal hypertension, J Hepatol, 63, 743, 10.1016/j.jhep.2015.05.022

G N Kalambokis, 2016, Red signs and not severity of cirrhosis should determine non-selective β-blocker treatment in Child-Pugh C cirrhosis with small varices: increased risk of hepatorenal syndrome and death beyond 6 months of propranolol use, Gut, 65, 1228, 10.1136/gutjnl-2016-311527

B S Madsen, 2016, Keep the sick from harm in spontaneous bacterial peritonitis: dose of beta blockers matters, J Hepatol, 64, 1455, 10.1016/j.jhep.2016.01.031

A Horvath, 2016, Randomised clinical trial: the effects of a multispecies probiotic vs. placebo on innate immune function, bacterial translocation and gut permeability in patients with cirrhosis, Aliment Pharmacol Ther, 44, 926, 10.1111/apt.13788

R Garcia-Martinez, 2013, Albumin: pathophysiologic basis of its role in the treatment of cirrhosis and its complications, Hepatology, 58, 1836, 10.1002/hep.26338

T Gustot, 2014, Beneficial role of G-CSF in acute-on-chronic liver failure: effects on liver regeneration, inflammation/immunoparalysis or both?, Liver Int, 34, 484, 10.1111/liv.12356

A Khanam, 2014, Altered frequencies of dendritic cells and IFN-gamma-secreting T cells with granulocyte colony-stimulating factor (G-CSF) therapy in acute-on- chronic liver failure, Liver Int, 34, 505, 10.1111/liv.12415

C K Kedarisetty, 2015, Combination of granulocyte colony-stimulating factor and erythropoietin improves outcomes of patients with decompensated cirrhosis, Gastroenterology, 148, 1362, 10.1053/j.gastro.2015.02.054

R Anty, 2014, Low levels of 25-hydroxy vitamin D are independently associated with the risk of bacterial infection in cirrhotic patients, Clin Transl Gastroenterol, 5, e56, 10.1038/ctg.2014.6

R Anty, 2014, Prophylaxis of bacterial infections in cirrhosis: is an optimal 25-OH vitamin D level required?, J Hepatol, 61, 965, 10.1016/j.jhep.2014.06.039

X Ariza, 2012, Risk factors for resistance to ceftriaxone and its impact on mortality in community, healthcare and nosocomial spontaneous bacterial peritonitis, J Hepatol, 56, 825, 10.1016/j.jhep.2011.11.010

M G Ison, 2016, Empiric treatment of nosocomial spontaneous bacterial peritonitis: one size does not fit all, Hepatology, 63, 1083, 10.1002/hep.28476

M Bartoletti, 2014, Epidemiology and outcomes of bloodstream infection in patients with cirrhosis, J Hepatol, 61, 51, 10.1016/j.jhep.2014.03.021

K Sargenti, 2015, Healthcare-associated and nosocomial bacterial infections in cirrhosis: predictors and impact on outcome, Liver Int, 35, 391, 10.1111/liv.12625

S Piano, 2016, The empirical antibiotic treatment of nosocomial spontaneous bacterial peritonitis: results of a randomized, controlled clinical trial, Hepatology, 63, 1299, 10.1002/hep.27941

R Jalan, 2014, Toward an improved definition of acute-on-chronic liver failure, Gastroenterology, 147, 4, 10.1053/j.gastro.2014.05.005